| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 35.919 | 44.357 | 46.976 | 55.474 | 53.212 | 47.415 | 43.841 | 56.716 | 59.771 | 110.814 |
| Total Income - EUR | 35.933 | 44.359 | 46.977 | 55.476 | 59.060 | 53.371 | 47.885 | 56.717 | 63.815 | 111.276 |
| Total Expenses - EUR | 27.525 | 33.005 | 33.093 | 40.791 | 48.140 | 48.441 | 47.138 | 51.267 | 62.070 | 81.866 |
| Gross Profit/Loss - EUR | 8.408 | 11.355 | 13.884 | 14.685 | 10.920 | 4.930 | 747 | 5.449 | 1.745 | 29.410 |
| Net Profit/Loss - EUR | 7.330 | 10.911 | 13.414 | 14.130 | 10.387 | 4.634 | 346 | 4.909 | 1.170 | 24.704 |
| Employees | 5 | 0 | 6 | 7 | 6 | 6 | 6 | 6 | 6 | 6 |
Check the financial reports for the company - Novastarmed - Sev Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.720 | 6.514 | 9.944 | 9.258 | 7.656 | 6.318 | 5.879 | 5.641 | 4.004 | 3.971 |
| Current Assets | 5.513 | 7.405 | 8.386 | 8.058 | 15.207 | 16.915 | 7.253 | 16.253 | 17.081 | 37.487 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 1.755 | 3.228 | 2.253 | 2.924 | 3.060 | 1.467 | 3.798 | 4.660 | 0 | 2.872 |
| Cash | 3.758 | 4.177 | 6.133 | 5.133 | 12.148 | 15.448 | 3.455 | 11.593 | 17.081 | 20.542 |
| Shareholders Funds | 7.945 | 11.520 | 14.012 | 14.182 | 11.018 | 5.253 | 5.483 | 10.409 | 11.547 | 35.023 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 3.523 | 2.399 | 4.318 | 3.134 | 11.846 | 17.980 | 7.648 | 11.485 | 9.538 | 6.434 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Novastarmed - Sev Srl